Ovid’s Therapy for Angelman Syndrome OV101 Is Focus of Clinical Trials
Ovid Therapeutics is conducting two clinical trials assessing its lead candidate OV101 for the treatment of adolescents and adults with Angelman syndrome. Both trials are currently enrolling participants. “Ovid has a clear strategy and business plan to build a neurology company focused on rare disorders of the brain,” Jeremy…